Launch and Commercialization of the Medical Materials Project
First written in FY2019-Q1. 5 of 10 entries say "Advanced", first in FY2019. Latest entry: FY2026.
2 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「We launched our proprietary brand Irigrasia in April 2025, using our proprietary nanoemulsion technology. Its high perceived absorption has received strong customer reviews, and going forward we will accelerate expansion into high-functionality markets, including doctor-developed cosmetics.」
Nanoemulsion technology has advanced from the R&D and adoption-review stage to the launch of a proprietary brand and expansion into high-functionality markets. - FY2024AdvancedAnnual report
「In February 2024, we filed the first patent related to the compounds under development. Going forward, we will expand safety and pharmacokinetic data and clarify the mechanisms of action of the compounds under development toward out-licensing to major pharmaceutical companies, with the aim of early practical implementation. We are also applying nanoemulsion technology, which can dramatically improve the absorption of various drugs, to cosmetic ingredients, and 2 domestic brand holders are considering adopting it.」
In the life sciences field, the company progressed to filing its first patent, expanding data toward out-licensing, and having 2 domestic brand holders consider adopting its nanoemulsion technology. - FY2023AdvancedAnnual report
「In the life sciences field, we are conducting drug-discovery research on activators of autophagy, an intracellular homeostatic process thought to be associated with various lifestyle-related diseases that worsen with age, in collaboration with multiple universities and research institutions. We have also developed proprietary nanoemulsion technology capable of dramatically improving the absorption of various drugs, initially applying it to cosmetic ingredients and advancing R&D toward practical implementation.」
In the life sciences field, the company is advancing drug-discovery research with universities and research institutions, while developing nanoemulsion technology and moving toward research on its application and practical implementation in cosmetic ingredients. - FY2021AdvancedAnnual report
「The Medical Materials Project, previously established within the R&D Division, was reorganized into the Life Sciences Development Division in March 2021. In collaboration with universities and other companies, the division is advancing development primarily in drug discovery, including novel active pharmaceutical ingredient compounds, and in life sciences, focusing on nanoemulsion-based products.」
The Medical Materials Project was reorganized into the Life Sciences Development Division in March 2021, advancing toward a development structure for drug discovery and nanoemulsion-based products. - FY2020RestatedAnnual report
「Leveraging its location in Kobe Biomedical Innovation Cluster, the Medical Materials Project is advancing development in collaboration with universities and other companies, focusing on drug discovery involving development of active pharmaceutical ingredients and life sciences involving development of nanoemulsion-based products.」
The company continues to pursue commercialization of medical materials by advancing development in the drug-discovery and life sciences fields through collaboration with universities and other companies. - FY2020-Q3RestatedAnnual report
「For OPV (organic photovoltaics), we are advancing the practical application of mass-produced products and seeking to expand applications, while pursuing commercialization of medical materials through collaboration with universities and others.」
The company has reconfirmed its policy of pursuing commercialization of medical materials while advancing collaboration with universities and others. - FY2020-Q2RestatedAnnual report
「For OPV (organic photovoltaics), we aim to expand sales channels through mass production, while also pursuing commercialization of medical materials by advancing collaboration with universities and others.」
The company has reconfirmed its policy of mass-producing OPV and expanding sales channels, while commercializing medical materials through collaboration with universities and others. - FY2020-Q1RestatedAnnual report
「For OPV (organic photovoltaics), we aim to expand sales channels through mass production, while also broadening the range of themes in medical materials by advancing collaboration with universities and others, with the goal of commercializing the business.」
The company has reconfirmed its policy of advancing collaboration with universities and others in medical materials, expanding development themes and pursuing commercialization. - FY2019AdvancedAnnual report
「In the medical materials field, we will assign dedicated personnel and advance development of drug-discovery support materials and highly pharmacologically active materials through industry-government-academia collaboration with universities and others, while leveraging the benefits of being located in Kobe's Biomedical Innovation Cluster.」
The Medical Materials Project has moved into a specific development phase through the assignment of dedicated personnel and industry-government-academia collaboration with universities and others. - FY2019-Q1First statedAnnual report
「The R&D Division has begun launching the Medical Materials Project and is pursuing it with a sense of urgency to translate it into a business.」
The company has newly begun the Medical Materials Project and has, for the first time, explicitly identified R&D aimed at commercialization as a measure to pursue.